alpha-mannosidosis
Metabolic · 2025–2025
2decisions
1medicine
2carried consumer input
2individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| velmanase alfa Enzyme replacement therapy for the treatment of non-neurological manifestations in patients with alpha-mannosidosis. | Dec 2025 | Recommended with restriction | 1 individuals |
| velmanase alfa Enzyme replacement therapy for the treatment of non-neurological manifestations in patients with alpha-mannosidosis. | Dec 2025 | Deferred | 1 individuals |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.